Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioLineRx has recruited first subject in a double-blind, single-site, placebo controlled Phase I trial to evaluate BL-1021 as a treatment for neuropathic pain.
Subscribe to our email newsletter
In the study, BioLineRx expects to investigate the safety, phamacokinetics and tolerability of BL-1021 in healthy volunteers.
The primary endpoints of the study are to assess the safety and tolerability of a single administration or multiple administrations of BL-1021.
However, the secondary endpoints are the pharmacokinetics of single or multiple doses of BL-1021 in healthy subjects.
BioLineRx CEO Kinneret Savitsky said based on the promising results from their pre-clinical studies, they believe it has the potential to provide improved efficacy without the side effects associated with many existing medications.